Reading NOTV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NOTV free→Reading NOTV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NOTV free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, NOTV is below typical. The valuation grid is empty, so there is no valuation read. The overall read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $0.04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted -0.00x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.47 → $-0.52 (-10.6% / 30d). 1 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 positive, 7 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$582.
How much price usually moves either way.
On a bad day, this stock has moved -$1,493.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $9,847.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'cautious' to 'mixed'.
The signal changed from cautious to mixed. Risk is elevated. The sector backdrop is a headwind. Earnings quality is loss making. Management is volatile and capital unfriendly. Recent financial performance is weak.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Inotiv needs to change how it works. This will help it manage debts.
Confirms:The court has approved the Chapter 11 restructuring plan.
Disproves:Further delays or rejections of the restructuring plan by the court.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NOTV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 4, 2026, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq had determined to delist the Company’s common shares, no par value per share (the “Common Shares”), in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM‑5101-1 as a result of the Company’s commencement of voluntary proceedings under Chapter 11 of the…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
A side-by-side read on sector standing, valuation, and risk versus Life Sciences Tools & Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NOTV Inotiv Inc | Below typical Show detailsSector percentile: 26 of 100 | — | elevated |
TMO Thermo Fisher Scientific | Above typical Show detailsSector percentile: 95 of 100 | fair | moderate |
DHR Danaher Corporation | Above typical Show detailsSector percentile: 97 of 100 | fair | moderate |
A Agilent Technologies | Above typical Show detailsSector percentile: 94 of 100 | full | moderate |
WAT Waters Corporation | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
19 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Implement restructuring via Chapter 11 to address financial obligations and reorganize the company.
Respond to Nasdaq's delisting notice due to failure to meet listing standards.
Address accelerated financial obligations triggered by Chapter 11 filing.
Bankruptcy or Receivership. On June 3, 2026 (i.e., the Petition Date), the Company Parties filed voluntary petitions to commence the Chapter 11 Cases in the Bankruptcy Court to implement the Plan effectuating the Restructuring in accordance with the Restructuring Support Agreement. Prior to commencing the Chapter 11 Cases, the Company commenced the solicitation of the Plan (the “Solicitation”) with a related disclosure statement (the “Disclosure Statement”). The Company has requested that the…
Entry Into a Material Definitive Agreement. Introductory Note On June 3, 2026, Inotiv, Inc. (the “Company”) filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission to report, among other matters, the filing by the Company and certain of its subsidiaries of voluntary petitions to commence proceedings under Chapter 11 of the United States Bankruptcy Code through a joint prepackaged plan of reorganization (the “Plan”). In that Form 8-K, there was a description of cert…
Entry into a Material Definitive Agreement. Restructuring Support Agreement On June 2 2026, the Company entered into a Restructuring Support Agreement (together with all exhibits and schedules thereto, the “Restructuring Support Agreement”) with: · certain lenders, or investment advisors, or holders of claims pursuant to the Company’s obligations under that certain credit agreement, dated as of November 5, 2021, between the Company, as borrower, the guarantors and lenders party thereto, and A…
Entry into a Material Definitive Agreement. On May 28, 2026, following receipt of consents from holders of a majority in aggregate principal amount of the outstanding 3.25% Convertible Senior Notes due 2027 (the “Convertible Notes”) of Inotiv, Inc. (the “Company”), the Company, as Issuer, BAS Evansville, Inc., as Guarantor, and U.S. Bank Trust Company, National Association, as successor in interest to U.S. Bank National Association, as Trustee, entered into the Second Supplemental Indenture (…